The corruption cases databases are a product of the staff of the International Bank for Reconstruction and Development / The World Bank. It is intended for general information purposes only. The findings, interpretations, and conclusions expressed in the Database do not necessarily reflect the views of the Executive Directors of The World Bank or the governments they represent. The World Bank does not guarantee the accuracy of the data included in this work. Neither the World Bank Group nor its officers or employees shall be liable for any losses that may result directly or indirectly from the use of or reliance upon such information.
Bribery of foreign officials, Falsification of books and records, Internal controls violations
No admission or denial of allegations
According to the US Department of Justice Report to Congress, Appendix C "Summaries of Foreign Corrupt Practices Act Enforcement Actions by the United States, January 1, 1998 - September 30, 2010," Diagnostic Products Corporation, at 109-110: From late 1991 through December 2002, DPC (Tianjin) Co., Ltd., a subsidiary of Diagnostics Product Corporation paid approximately $1.6 million in bribes in the form of illegal "commissions" to physicians and lab personnel employed at government-owned hospitals in China in exchange for agreements that the hospitals would obtain DPC Tianjin's products and services. In most cases, bribes were paid in cash. The "commissions," typically between 3 percent and 10 percent of sales, allowed DPC Tianjin to earn approximately $2 million in profits from the sales. DPC Tianjin pleaded guilty to violating the FCPA and paid criminal fine of $2 million; to resolve SEC charges, DPC agreed to the issuance of an order to cease-and-desist from future violations and to disgorge $2,038,727 and $749,895 in prejudgment interest to the SEC. Resulting Criminal Enforcement Actions: US v. DPC (Tianjin) Co., Ltd. (C.D. Cal., May 20, 2005); Resulting Civil/Administrative Enforcement Action: In the Matter of Diagnostic Products Corporation (May 20, 2005).
US Department of Justice Report to Congress, Appendix C "Summaries of Foreign Corrupt Practices Act Enforcement Actions by the United States, January 1, 1998 - September 30, 2010," Diagnostic Products Corporation, at 109-110, accessed at www.justice.gov/criminal/fraud/fcpa/docs/response3-appx-c.pdf; In the Matter of Diagnostic Products Corporation, US Securities and Exchange Commission, Administrative Proceeding File No. 3-11933, Order Instituting Cease and Desist Proceedings, May 20, 2005, accessed at http://www.sec.gov/litigation/admin/34-51724.pdf
Please help us ensure that StAR Asset Recovery Watch is as accurate and comprehensive as possible by sending us updated information regarding the cases currently in StAR Asset Recovery Watch, as well as information about cases for future inclusion in the database.
To report any errors or updated case information, please contact email@example.com. Please include the name of your organization, the country in which you reside, and "StAR Asset Recovery Watch" in the subject line.